Fatal Rhizopus Pneumonia in Allogeneic Stem Cell Transplant Patients Despite Posaconazole Prophylaxis: Two Cases and Review of the Literature  by Lekakis, Lazaros J. et al.
BRIEF ARTICLEFrom the
ton, K
Medic
3Infec
ternal
Financial d
Correspon
Mark
Street
ljleka2
Received M
 2009 Am
1083-8791
doi:10.101Fatal Rhizopus Pneumonia in Allogeneic Stem Cell
Transplant Patients Despite Posaconazole Prophylaxis:
Two Cases and Review of the Literature
Lazaros J. Lekakis,1 Amber Lawson,1 Jeanette Prante,2 Julie Ribes,2 Gregory J. Davis,2
Gregory Monohan,1 Ioannis G. Baraboutis,3 Athanasios T. Skoutelis,3 Dianna S. Howard1Posaconazole is a triazole with broad spectrum of activity against multiple fungi including members of the
fungal order Mucorales. This activity has been shown both in clinical and in vitro studies, which are critically
reviewed here. It has become very popular in prophylaxis in acute myelogenous leukemia (AML) induction
and in the graft-versus-host disease (GVHD) settings after 2 recent prospective trials that showed advantage
of posaconazole prophylaxis compared to fluconazole or itraconazole. In this report, 2 patients are pre-
sented, in whom, despite posaconazole prophylaxis, invasive and ultimately fatal Rhizopus pulmonary infec-
tions developed. These cases are similar to a previously reported case of Rhizopus infection in a stem cell
transplant recipient who also received posaconazole, indicating a potential newly recognized pattern of
breakthrough infections in patients receiving posaconazole prophylaxis.
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Posaconazole [1] is a triazole similar in structure to
itraconazole with broad-spectrum antifungal activity
including some activity against the fungal orderMucor-
ales. Its clinical efficacywas confirmedby 2 reported tri-
als [2,3] showing advantage of posaconazole as
a prophylactic agent compared to fluconazole and itra-
conazole in acute myelogenous leukemia (AML) and
graft-versus-host disease (GVHD) settings. Voricona-
zole has failed to show such a significant advantage [4]
compared to fluconazole in the prophylactic setting.
Despite problemswith its bioavailability [1], posacona-
zole is used widely, and reports of breakthrough fungal
infections have been rare. A pattern ofMucorales break-
through infection similar to that after the widespread
use of voriconazole [5,6] has not been established yet.1Markey Cancer Center, University of Kentucky, Lexing-
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/09/158-0001$36.00/0
6/j.bbmt.2009.04.007This article reports on2 cases of fatal pneumoniasby
Rhizopus microsporus despite posaconazole prophylaxis.PRESENTATION OF CASES
Case 1
A 63-year-old gentleman with refractory follicular
lymphoma received an allogeneic stem cell transplanta-
tion fromamatchedunrelateddonor (MUDallo-HCT)
after conditioning with busulfan (Bu), cyclophospha-
mide (Cy), and alemtuzumab (total dose5 60 mg.v.).
He had been diagnosed with follicular lymphoma 11
years before HCT and had been heavily pretreated.
After transplantation, he was never found to have pro-
gression of lymphoma, and bone marrow biopsies and
autopsy materials were negative for relapsed lymphoma
including a negative FISH for t(14;18) in the marrow.
He developed primary cytomegalovirus (CMV) infec-
tion 1 month after transplantation despite use of irra-
diated leukocyte-reduced blood products. He was
successfully treatedwith foscarnetbecauseof ganciclovir
failure. At about the same time, he was diagnosed with
uppergastrointestinal and skin acuteGVHD(aGVHD).
Systemic steroids and tacrolimus controlled the grade II
GVHD. Because of BK-hemorrhagic cystitis and the
CMV infection, steroids were rapidly tapered.
Five months after transplantation, coming back
from vacation, he presented with relapsed CMV
viremia and skin GVHD unsuccessfully controlled991
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day), foscarnet and concomitant prophylactic posaco-
nazole (200 mg orally 3 times a day with food) were
started. Several weeks later he presented with dyspnea
and tenderness at the Port-A-Cath placement site. The
port was removed and patient was admitted in the in-
tensive care unit with respiratory distress. He deterio-
rated and was intubated. Despite antibacterials,
liposomal amphotericin (AmBisome), posaconazole,
and intravenous immunoglobulin (IVIG) (for positive
parainfluenza type 2 in his respiratory secretions) he
expired several weeks later from progressive pneumo-
nia causing terminal respiratory failure. Autopsy
showed diffuse angioinvasive infection in the lung pa-
renchyma by nonseptate, right-angle branching, and
irregular ribbon-like hyphal organisms morphologi-
cally consistent with Mucorales infection (Figure 1).
The same hyphae caused mediastinal fat necrosis.
Lung tissue sent for culture demonstrated no hyphal
elements on direct examination and no growth was de-
tected after 6 weeks. Premortem bronchoalveolar la-
vage (BAL) and routine bronchial cultures grew rare
colonies of a Rhizopus species on inhibitory mold, sab-
ouraud dextrose, and yeast extract agars. The fungus
did not grow above 50C. The microscopic features
were consistent with a final identification of Rhizopus
microsporus var. microsporus [7] (see Figure 1). No evi-
dence of active parainfluenza or CMV pneumonia
was seen. Although posaconazole levels were neverFigure 1. (A, B) Angioinvasive mucorales infection with an intraluminal infec
methenamine silver stain200). (C, D) High-power morphology of hyphae on
branches. Also note the ‘‘bubble-like’’ appearance of hyphae seen in cross-sectio
stain 600).checked, he and his wife had confirmed the intake of
posaconazole with fatty food while he was treated
with this medication prophylactically as an outpatient.
Susceptibility testing using E-test strips (AB Biodisk,
Solna, Sweden) demonstrated a mean inhibitory con-
centration (MIC) for amphotericin B of 0.064 mg/
mL, posaconazole 3 mg/mL, and no zone of inhibited
growth for voriconazole (MIC.32 mg/mL). Although
definitive breakpoints have not been established for
mold testing, the Clinical Laboratory Standards Insti-
tute (CLSI) [7] have tentatively assigned MICs of
\1 mg/mL as susceptible,MIC of 2 mg/mL as interme-
diate, and those 4 mg/mL or above (in doubling dilu-
tions) as resistant for all 3 of the drugs tested. In fact,
posaconazole levels cannot be reliably maintained
above 1 mg/mL, and, in most cases, are going to be
well below 1 mg/mL for most of the dosing interval
[8-10]. Using these interpretative guidelines, only am-
photericin B gave a susceptible result, whereas posaco-
nazole falls into the intermediate and voriconazole into
the floridly resistant category. In vitro activities of pos-
aconazole, voriconazole, and amphotericin have been
evaluated by Sun et al. [11,12], who have found that
for Rhizopus species, the MIC50 and MIC90 con-
centrations of posaconazole were 1 mg/mL and
8 mg/mL, respectively, voriconazole was .64 mg/mL
for both MIC50 and MIC90, whereas those for
amphotericin B were 0.125 and 0.5 mg/mL, res-
pectively.ted clot in patient 1 (A, hematoxylin and eosin stain 200; B, Gomori
patient 1 demonstrating nonseptate, ribbon-like hyphae with right-angle
n. (C, hematoxylin and eosin stain600; D, Gomori methenamine silver
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A 63-year-old gentleman underwent a reduced-
intensity (RIC)MUDallo-HCTafter fludarabine (Flu)-
melphalan (Mel)-alemtuzumab (total dose5 60 mg.v.)
for refractory peripheral T cell lymphoma, not other-
wise specified (NOS). He had multiple opportunistic
infections posttransplant including CMV, BK-virus
hemorrhagic cystitis, parainfluenza type 3, Mycobacte-
rium fortuitum, recurrent Strongyloides stercoralis superin-
fections and multiple bacterial infections. In addition to
the peritransplant in vivo T cell depletion with alemtu-
zumab, his immunosuppression had been accentuated
by systemic steroids, mycophenolate mofetil (MMF),
tacrolimus, and a short course of infliximab for grade
III skin and gastrointestinal aGVHD, which evolved
into chronic extensive persistentGVHD (cGVHD). Al-
thoughhewas receiving steroids and19days after hehad
been started on prophylactic oral posaconazole (200 mg
orally 3 times a daywith foodpreparedbyhis very caring
family) he was found to have a new 1.7 cm right middle
lobe nodule by both chest X-ray and high-resolution
computed tomography (CT) of the chest. The lesion
was not present in chest X-rays performed 11 and 13
days after the initiation of posaconazole. Biopsy of the
lesion showed wide, ribbon-like, nonseptate hyphae
consistent with Mucorales infection. Rare colonies of
Rhizopus species were detected in primary culture on
inhibitory mold, sabouraud dextrose, and brain heart
infusion agars. The colonies grew well at temperatures
.50C. The microscopic features were consistent with
a final identification of Rhizopus microsporus var. rhizopo-
diformis [7]. Posaconazole was continued and liposomal
Amphotericin (AmBisome) was added. A new chest
CTchest 6 days later showed enlargement of the nodule
to 2.3 cm. He never suffered relapse of his lymphoma
and his hematopoiesis had been consistently of donor
origin. He developed significant and progressively
worse respiratory distress and, after a few days of clinical
deterioration, the family decided to discontinue active
treatment. Susceptibility testing (performed postmor-
tem) using E-test strips demonstrated an MIC for
amphotericin B of 0.064 mg/mL, for posaconazole
3 mg/mL, and no zone of inhibited growth for voricona-
zole (MIC.32 mg/mL). Similar to the previous isolate,
these MIC values likely reflect a lack of susceptibility to
both posaconazole and voriconazole, but susceptibility
to amphotericin B.DISCUSSION
Posaconazole has clinical efficacy as a prophylactic
agent for patients who undergo induction chemother-
apy for AML or for those who develop systemic
GVHD and require high doses of systemic corticoste-
roids [1]. Posaconazole is only available in an oral
solution form [1], and, although its bioavailability isclosely dependent on its intake with fatty meals, it
has gained widespread popularity. It has also been suc-
cessfully used for treatment, although most of the data
being available are from prophylaxis studies because
no prospective posaconazole treatment studies have
been conducted except from a trial in esophageal Can-
didiasis in the HIV setting [13].
Its specific efficacy against Rhizopus and other
Mucorales species has been documented in case reports
and data from nonrandomized compassionate use of
posaconazole.
Greenberg et al. [14] described the survival of 19 of
24 patients with documented Mucorales infection with
compassionate use of posaconazole. Patients had failed
or could not tolerate other antifungal agents. He em-
phasized the importance of surgical resection and sta-
bilization or improvement of the underlying
immunosuppressed state.
Similarly, van Burik et al. [15] conducted a retro-
spective study in 69 patients with proved and 22 pa-
tients with probable Mucorales infection. The success
rate was 60%, and stable disease was observed in an ad-
ditional 21% of patients after 12 weeks of treatment.
Tobon et al. [16] reported a case of amphotericin
B-resistant invasive Rhizopus infection in a heart-lung
transplant patient that responded to posaconazole.
Peel et al. [17] used posaconazole as first-line agent
for disseminated Rhizopus microsporus infection in a pa-
tient with systemic lupus erythematosus.
Early institution of posaconazole for Rhizopus infec-
tions is paramount as emphasized byKok et al. [18], who
reported 2 salvages of patients with rhino-orbital Rhizo-
pus oryzae after early institution of posaconazole in
conjunction with surgical debridement. Rutar et al. [19]
described a case of periorbital Rhizopus infection effec-
tively treated with posaconazole after liposomal ampho-
tericin B had been withdrawn because of side effects and
lack of improvement. The Rhizopus strain was highly
susceptible to posaconazole in vitro. Other reports fur-
ther suggest clinical efficacy of posaconazole against
Rhizopus species [20–22].
In vitro, there are mixed data in terms of posacona-
zole activity against Rhizopus. Arikan et al. [23] re-
ported that posaconazole was more potent in vitro
against clinical isolates of Rhizopus oryzae compared
to voriconazole, itraconazole, and amphotericin B.
Perkhofer et al. [24] showed that posaconazole en-
hanced the in vitro activity of amphotericin B against
the hyphae form of the Mucorales fungi, including iso-
lates of Rhizopus microsporus, but not Rhizopus oryzae.
It seems that there is heterogeneity in in vitro sus-
ceptibility to posaconazole and amphotericin B among
the different Mucorales species (eg, Rhizomucor species
may have relatively lower MICs) [25].
Murine model data reported first by Rodriguez
et al. [26] and then by Ibrahim et al. [27] showed that
addition of posaconazole to amphotericin products
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cies. Barchiesi et al. [28] reported only limited posaco-
nazole activity as a prophylactic measure in a murine
model of Rhizopus oryzae infection.
In the clinic, Vyzantiadis et al. [29] reported a fatal
case of rhinocerebral Rhizopus oryzae infection in a pa-
tient treated with steroids for ITP. The fungus was re-
sistant to both Amphotericin B and to posaconazole
(MIC 4 mg/mL), which was later coadministered.
The 2 cases herein described raise questions as to
how strong and universal is the prophylaxis against
Rhizopus species with posaconazole. This article con-
firms similar concerns raised by the recent case report
of breakthrough Rhizopus microsporus in a post-HCT
patient despite posaconazole prophylaxis [30].
It is possible that some strains of Rhizopus are in-
herently resistant to, and can be selected for, posacona-
zole prophylaxis. The fact that there has been no
pattern observed so far of breakthrough Aspergillus in-
fections after the widespread use of posaconazole, but
there are already 3 cases of Rhizopus species break-
through infections raises the possibility that break-
through Rhizopus infection could be because of
limited activity of posaconazole against some Rhizopus
species and not because of bioavailability issues of the
compound. It is interesting to note that all 3 of the re-
ported prophylaxis failures have involved varieties of
the Rhizopus microsporus group. Furthermore, Verweij
et al. [31] reported a fatal case of Rhizopus microsporus
despite treatment with posaconazole and liposomal
amphotericin B. This is significant in that theMicrospo-
rus group makes up about 15% of rhinocerebral infec-
tions because of the Rhizopus species [26].
The routine use of fungal cell wall antigens (galac-
tomannan, beta-glucan) [32,33] has been useful in the
early detection and has made the preemptive treatment
of invasive fungal infections feasible, but they do not
detect Mucorales infections. Recently, Kasai et al. [34]
reported a real-time quantitative PCR assay targeting
the 28S rRNA of the clinically most important agents
of Mucorales. By using this method, early detection of
infections was feasible in the blood, tissue, or BAL
from infected rabbits. If this method is validated in hu-
man specimens, it may allow for an early diagnosis and
treatment of human Mucorales.
Because of the recent reports showing improved
prophylaxis with posaconazole in AML induction
and steroid-treated GVHD, we believe that it should
be used as the standard for prophylaxis for patients
who can reliably absorb it. Nonetheless, a very low
threshold should be set for CT imaging of the lungs,
paranasal sinuses, or brain in the appropriate setting.
This will help in the early detection of either Rhizopus
or other breakthrough fungal infection and may
improve the—disappointing so far—prognosis of
those patients. The optimal routine use of serologic
markers (beta-glucan or galactomannan) in additionto posaconazole is expected to help further in the de-
tection of invasive fungal infections. Finally, documen-
tation of compliance and bioavailability by measuring
posaconazole levels are expected to be useful clinically.ACKNOWLEDGMENTS
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